Clinical Efficacy and Safety of Oral Supplement of Allium ascalonicum L. in Patients with Allergic Rhinitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17013331

Enrollment

Unknown

Registered

2017-11-10

Start date

2017-11-15

Completion date

Unknown

Last updated

2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Interventions

1:Cetirizine 10 mg 1 tablet hs+supplement of Allium ascalonicum L. (500 mg) 3 capsules bid

2:Cetirizine 10 mg 1 tablet hs+placebo 3 capsules bid

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Subjects will be male and female, aged 18-60 years old who were diagnosed with mild-persistent allergic rhinitis (according to ARIA 2008 guidelines) with previous history of positive skin prick test or presence of positive skin prick test to at-least 1 allergen during screening period. They must have total nasal symptom scores (TNSS) = 6 within prior 2 weeks and the score of nasal congestion must not exceed 2 (= 2). All subjects must be explained and clearly understand the details of this research protocol, and give their written informed consent before entering the study.

Exclusion criteria

Exclusion criteria: Subjects were excluded from the study if they had: (1) marked anatomical abnormality of nose such as nasal septum deviation, nasal polyposis, unilateral obstruction; (2) infection of respiratory tract within 2 weeks before the study; (3) use of oral or intranasal corticosteroids within 4 weeks before the study; (4) nasal surgery within 4 weeks before the study; (5) currently on immunotherapy or previously received immunotherapy within 1 year before entering the study; (6) hypersensitivity of cetirizine or ingredient of the drug; (7) hypersensitivity of Allium ascalonicum L. or chemical in Allium ascalonicum L.; (8) history of asthma, cancer, hepatic diseases (AST, ALT > 1.5 times of the upper limit of normal range) or renal disease (eGFR < 50 ml/min), heart disease (using the digoxin); (9) pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Total nasal and ocular symptom scores (TNSS and TOSS);Visual analog scale of overall symptoms scores (VAS);Quality of Life;Subject satisfaction;Nasal cytology;Nasal airway resistance (NAR);Any adverse event;Laboratory investigation for complete blood count (CBC), creatinine level (Cr), AST, and ALT;	—

Countries

Thailand

Contacts

Public ContactSoraya Klinprung

Faculty of Medicine, Chiang Mai University

nampu_nre@hotmail.com+66 8 14077049

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026